CohBar Inc (OTCPK:CWBR)
$ 0.5 -0.014 (-2.72%) Market Cap: 1.45 Mil Enterprise Value: -10.86 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

CohBar Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 04:00PM GMT
Release Date Price: $29.04 (-0.04%)
Thomas Yip
H.C. Wainwright & Co., LLC - Analyst

Welcome to the H.C. Wainwright 5th Annual NASH Conference. For our next presentation, we have Dr. Joseph Sarret, CEO of CohBar, a clinical stage company developing mitochondria-based therapeutics for chronic diseases. Dr. Sarret, very good to have you with us. Please go ahead with your presentation.

Joseph Sarret
CohBar, Inc. - CEO & Director

Thanks, Thomas. Appreciate the opportunity here to speak with you today and tell you more about CohBar and the exciting work we are doing in the area of NASH. Just as a reminder, CohBar is a public company so typical forward-looking statement warnings apply to my remarks today.

So CohBar, in terms of our overall approach, what we are doing is we are leveraging the power of mitochondrial genome to develop novel peptide therapeutics. As you may be aware, people have been looking at the nuclear genome for quite some time, but mitochondrial has been largely overlooked. I think for a couple of reasons. One is people tend to think of mitochondria in terms of ATP

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot